Related Experiment Video
Updated: Apr 28, 2026
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
[Therapeutic targeted approaches on androgen receptors in prostate cancer]
1Service d'oncologie, HIA Val-de-Grâce, boulevard Port-Royal, 75005 Paris, France.
Abstract:
The treatment of metastatic prostate cancer since the 1940s is based on the consideration of oncogenic addiction to its androgen receptor (AR). The significant improvement in survival outcomes over the past decade depends not only on the development of effective cytotoxic chemotherapy but also new molecules targeting the AR or decreasing testosterone levels, even in case of castration-resistant cancer. In this review, we summarize the structure and function of the RA, the mechanisms of androgen suppression, the concept of resistance to castration, historical targeted treatment on the AR and those recently marketed as abiraterone acetate and enzalutamide.
Insights
Metastatic prostate cancer treatment targets the androgen receptor (AR) and testosterone levels. Advances include chemotherapy and new drugs like abiraterone acetate and enzalutamide for castration-resistant disease.
Area of Science:
- Oncology
- Molecular Biology
- Endocrinology
Context:
- Prostate cancer treatment has historically relied on targeting the androgen receptor (AR).
- Recent decades show survival improvements due to chemotherapy and novel AR-targeting agents.
- Understanding AR signaling is crucial for managing advanced prostate cancer.
Purpose:
- To review the structure and function of the androgen receptor (AR).
- To elucidate mechanisms of androgen suppression and castration resistance.
- To summarize historical and recent targeted therapies for metastatic prostate cancer.
Summary:
- The androgen receptor (AR) is a key driver in prostate cancer, making it a primary therapeutic target.
- Therapeutic strategies have evolved from general androgen deprivation to specific AR pathway inhibitors.
- Newer agents like abiraterone acetate and enzalutamide demonstrate efficacy in castration-resistant prostate cancer (CRPC).
Impact:
- This review provides a comprehensive overview of AR-targeted therapies for prostate cancer.
- It highlights the progression of treatment strategies, including management of resistance mechanisms.
- The information is valuable for clinicians and researchers in advancing prostate cancer care.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...